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Abstract
IMPORTANCE Despite intensive treatment, hospitalized patients with acute decompensated heart
failure (ADHF) have a substantial risk of postdischarge mortality. Limited data are available on the
possible differences in the incidence andmechanisms of death among patients with heart failure
with reduced ejection fraction (HFrEF), heart failure with midrange ejection fraction (HFmrEF), and
heart failure with preserved ejection fraction (HFpEF).
OBJECTIVES To examine the incidences andmode of postdischargemortality among patients with
ADHF and to compare the risk profile among patients with HFrEF, HFmrEF, and HFpEF.
DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study of 4056 patients
hospitalized for ADHF analyzed data from 3717 patients who were discharged fromOctober 1, 2014,
to March 31, 2016. Data analysis was performed from April 1 to August 31, 2019.
EXPOSURES Death among patients with ADHF after hospital discharge.
MAINOUTCOMES ANDMEASURES All-cause death and cause of postdischargemortality after the
index hospitalization by left ventricular ejection fraction (LVEF) subgroup.
RESULTS A total of 3717 patients (mean [SD] age, 77.7 [12.0] years; 2049 [55.1%]male) were
included in the study. Themean (SD) LVEF at baseline was 46.4% (16.2%). Among 3717 enrolled
patients, 1383 (37.2%) were categorized as having HFrEF (LVEF, <40%), 703 (18.9%) as having
HFmrEF (LVEF, 40%-49%), and 1631 (43.9%) as having HFpEF (LVEF,50%). The incidence and
causes of death were evaluated after discharge from the index hospitalization. Themedian follow-up
period was 470 days (interquartile range, 357-649 days), and the 1-year follow-up rate was 96%.
During follow-up, all-cause death occurred in 848 patients (22.8%; HFrEF group: 298 [21.5%; 95%
CI, 19.5%-23.8%]; HFmrEF group: 158 [22.5%; 95% CI, 19.5%-25.7%]; and HRpEF group: 392
[24.0%; 95% CI, 22.0%-26.2%]; P = .26), cardiovascular deaths occurred in 523 patients (14.1%;
HFrEF group: 203 [14.7%; 95% CI, 12.9%-16.6%]; HFmrEF group: 97 [13.8%; 95% CI, 11.4%-16.5%];
and HFpEF group: 223 [13.7%; 95% CI, 12.1%-15.4%]; P = .71), and sudden cardiac death occurred in
98 patients (2.6%; HFrEF group: 44 [3.2%; 95%CI, 2.4%-4.2%]; HFmrEF group: 14 [2.0%; 95%CI,
1.2%-3.3%]; and HFpEF group: 40 [2.5%; 95% CI, 1.8%-3.3%]; P = .23). The risks of causes of death
were similar among the subtypes.
CONCLUSIONS ANDRELEVANCE Themode of death was similar among the heart failure subtypes.
Given the nonnegligible incidence of sudden cardiac death in patients with HFpEF found in this study,
further studies appear to be warranted to identify a high-risk subset in this population.
JAMA Network Open. 2020;3(5):e204296. doi:10.1001/jamanetworkopen.2020.4296
Key Points
Question Are there differences in the
mode of death after hospital discharge
in patients with reduced, midrange, and
preserved left ventricular ejection
fraction?
Findings In this cohort study of 3717
hospitalized patients with acute
decompensated heart failure with a
median follow-up of 470 days, 848
patients died (523 cardiovascular deaths
and 98 sudden cardiac deaths). The
risks of each cause of death were
comparable among the patients with
heart failure with reduced, midrange,
and preserved ejection fraction.
Meaning This study found
nonnegligible incidence of sudden
cardiac death in patients with heart
failure with preserved ejection fraction;
further study appears to be warranted
to identify a high-risk subset in this
population.
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Introduction
Heart failure has been an increasing public health concern, and hospitalization rates and costs of care
for heart failure remain high.1 Substantial progress has beenmade in themanagement of chronic
ambulatory heart failure with the availability of drugs such as β-blockers, angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), andmineralocorticoid receptor
antagonists (MRAs). However, morbidity andmortality among patients with heart failure are still
high.2-5 Hospitalized patients with acute decompensated heart failure (ADHF) had an annual
mortality rate of approximately 20%, which is higher than the rates among patients with chronic
ambulatory heart failure.6,7 However, the incidence andmechanisms of death among patients with
ADHF who are discharged from the hospital have not been well characterized. A better
understanding of the cause andmode of death in these patients may lead to better insights into the
underlying pathophysiologic mechanisms and new treatments for improving patient outcomes. In
addition, limited data are available for the possible differences in the mode of mortality among
patients with heart failure with reduced ejection fraction (HFrEF), heart failure with midrange
ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). Therefore, we
aimed to assess the prevalence andmode of mortality among patients with ADHF hospital after
discharge and then compare the risk profile among patients with HFrEF, HFmrEF, and HFpEF.
Methods
StudyDesign
The study design and primary results of the Kyoto Congestive Heart Failure (KCHF) registry have
been reported previously.8,9 In brief, the KCHF registry was a multicenter, prospective cohort study
that enrolled 4056 consecutive hospitalized patients with ADHF. The study was conducted from
October 1, 2014, toMarch 31, 2016, at 19 centers in Japan after approval of each participating center’s
ethics committee or institutional review board. A waiver of informed consent was granted by the
institutional review boards because the studymet the conditions of the Japanese ethical guidelines
for epidemiologic study and the US policy for protecting human research participants. This
prespecified post hoc analysis was approved by institutional review boards of each participating
institution. This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.
Among the 4056 enrolled patients in the KCHF registry, 3785 patients (93.3%)were discharged
after the index hospitalization for ADHF. Clinical follow-up data were collected in October 2017, and
the median follow-up period was 470 days. The attending physicians or research assistants at each
participating facility collected clinical events data after the index hospitalization from hospital
medical records or from patients, their relatives, or their referring physicians (with patient consent).
After excluding 57 patients whowere unavailable for follow-up after discharge and 11 patients
who had a missing left ventricular ejection fraction (LVEF) measurement at baseline, a total of 3717
patients were included in the current analysis. Patients were divided based on their LVEF at baseline:
less than 40% (HFrEF), 40% to 49% (HFmrEF), and 50% or higher (HFpEF). The eFigure in the
Supplement shows the selection of these patients from the overall KCHF population. Data analysis
was performed from April 1 to August 31, 2019.
Patients’ baseline characteristics, including age, height, bodyweight, blood pressure, heart rate,
laboratory data, and echocardiographic data, were recorded or measured at the time of hospital
discharge. A baseline medication was defined as a medication at the time of discharge. Incident
death and the cause of death were adjudicated up to 1 year. The causes of death were adjudicated by
a central clinical events committee on the basis of prespecified criteria and were classified into
cardiovascular death or noncardiovascular death. Cardiovascular death comprised death due to heart
failure exacerbation, acute coronary syndrome, stroke and intracranial hemorrhage, or fatal
ventricular arrhythmia; vascular-related death; sudden cardiac death (SCD); and other cardiac death
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causes. SCDwas defined as unexplained death of a previously stable patient, including fatal
ventricular arrhythmia and cardiac arrest. Noncardiovascular deaths includedmalignant tumors,
infection (including pneumonia), renal failure, liver failure, respiratory failure, bleeding, and
other causes.
Statistical Analysis
Categorical variables are expressed as numbers (percentages) and were compared using the χ2 test
or the Fisher exact test, as appropriate. Continuous variables are expressed as means (SDs) or
medians and interquartile ranges. On the basis of their distribution (qualitatively judged by histogram
and Q-Q plot), continuous variables were compared with an unpaired, 2-tailed t test when normally
distributed or with theWilcoxon rank sum test when not normally distributed. Two-sided P < .05 was
considered statistically significant. The Kaplan-Meier method was used to estimate cumulative
incidence of events, and differences were compared using the log-rank test. A Cox proportional
hazards regressionmodel was used to evaluate the association between each variable and the
incidence of all-cause death, cardiovascular death, and noncardiovascular death. Candidate variables
for themultivariable model included age, sex, hypertension, diabetes, atrial fibrillation, anemia,
chronic kidney disease, serum albumin level, blood urea nitrogen (BUN) level, and prescription of
β-blockers, ACEIs or ARBs, andMRAs at discharge. All variables were selected a priori because they
are risk factors for death or because of their ability to confound the association. Proportional hazards
assumption violationswere estimated by generalized linear regression of scaled Schoenfeld residuals
on time. Continuous variables were dichotomized bymedian values or clinically meaningful
reference values.
We introduced a bayesian network to estimate associations between risk factors andmortality.
A bayesian network is a probabilistic graphical model in which conditional dependencies among
multiple factors are represented by edges. We constructed a bayesian network and assumed
multinomial distribution for the outcome variable and binomial distribution for the other variables.
With the use of the data without any missing values, the posterior distributions of variables were
obtained using theMarkov chain Monte Carlo method. We set 4 separate sampling sequences, each
consisting of 1000 random samples, half of which were discarded for convergence. Sampling
convergence was evaluated using Gelman-Rubin statistics and by visually inspecting trace plots. All
prior variables were set as noninformative.
Statistical analyses were performed using JMP, version 14.0.0 (SAS Institute Inc) and R, version
3.5.1 (R Foundation for Statistical Computing), with probabilistic programming language Stan (Stan
Development Team) for all bayesian analyses.
Results
Patient Characteristics
A total of 3717 patients (mean [SD] age, 77.7 [12.0] years; 2049 [55.1%] male) were included in the
study. A total of 1000 patients (26.9%) had ischemic heart failure. The mean (SD) heart rate was
71/min (13/min), the mean (SD) systolic blood pressure was 116 (18) mmHg, and themean (SD)
diastolic blood pressure was 64 (12) mmHg. Themean (SD) LVEF at baseline was 46.4% (16.2%).
Among the 3717 enrolled patients, 1383 (37.2%) were categorized as having HFrEF (LVEF, <40%),
703 (18.9%) as having HFmrEF (LVEF, 40%-49%), and 1631 (43.9%) having as having HFpEF (LVEF,
50%).
Comparisons of baseline patient characteristics among the 3 groups andmissing values in each
variable are given in Table 1. Older agewas associatedwith increased likelihood of LVEF (mean [SD]
age in HFrEF group: 73.8 [13.6] years; mean [SD] age in HFmrEF group: 78.1 [11.0] years; and mean
[SD] age in HFpEF group: 80.7 [9.9] years; P < .001), and an increased prevalence of LVEF among
womenwas observed (HFrEF group: 458 [33.1%]; HFmrEF: 283 [40.3%]; and HFpEF: 927 [56.8%];
JAMANetworkOpen | Cardiology Mode of Death Among Japanese Adults With Heart Failure
JAMA Network Open. 2020;3(5):e204296. doi:10.1001/jamanetworkopen.2020.4296 (Reprinted) May 7, 2020 3/12
Downloaded From: https://jamanetwork.com/ by a Kyoto University User  on 05/13/2020
P < .001). An ischemic origin was most frequent in patients with HFrEF, whereas hypertension and
atrial fibrillation were most frequent in patients with HFpEF.
Incidence of Death
Themedian follow-up period was 470 days (interquartile range, 357-649 days) after discharge, and
the 1-year follow-up rate was 96%. During the follow-up period, 848 deaths were observed, and the
overall mortality rate was 22.8%. Causes of death were adjudicated as cardiovascular deaths in 523
patients (14.1%; 61.7% of total mortality) and noncardiovascular deaths in 322 patients (8.7%; 38.0%
of total mortality). The causes of cardiovascular death included heart failure exacerbation in 324
patients (8.7%), SCDs in 98 patients (2.6%), stroke or intracranial hemorrhage in 38 patients (1.0%),
acute coronary syndrome in 9 patients (0.2%), and vascular-related deaths in 13 patients (0.3%).
The causes of noncardiovascular death included infection in 122 patients (3.3%), malignant tumor in
71 patients (1.9%), and respiratory failure in 30 patients (0.8%) (Table 2).
The observedmodes of deaths among the 3 groups are compared in Figure 1. No significant
differences were found among the 3 groups with respect to all-cause death (HFrEF group: 298
patients [21.6%; 95% CI, 19.5%-23.8%]; HFmrEF group: 158 patients [22.5%; 95% CI, 19.5%-25.7%];
and HFpEF group: 392 patients [24.0%; 95% CI, 22.0%-26.2%]; P = .26), cardiovascular death
(HFrEF group: 203 patients [14.7%; 95% CI, 12.9%-16.6%]; HFmrEF group: 97 patients [13.8%; 95%









(n = 1631) P value
Age, mean (SD), y 77.7 (12.0) 73.8 (13.6) 78.1 (11.0) 80.7 (9.9) <.001
Male 2049 (55.1) 925 (66.9) 420 (59.7) 704 (43.2) <.001
BMI, mean (SD) 22.9 (4.5) 22.9 (4.6) 22.7 (4.2) 23.0 (4.4) .43
LVEF, mean (SD), % 46.4 (16.2) 29.1 (7.1) 44.3 (2.9) 61.9 (7.5) <.001
Ischemic origin 1000 (26.9) 534 (38.6) 234 (33.3) 232 (14.2) <.001
Blood pressure, mean (SD),
mm Hg
Systolic 116 (18) 112 (17) 119.5 (17.9) 118 (18) <.001
Diastolic 64 (12) 64 (13) 65 (12) 64 (12) .007
Heart rate, mean (SD), /min 71 (13) 72 (13) 71 (12) 70 (13) <.001
Comorbidities
Hypertension 2690 (72.4) 911 (65.9) 536 (76.2) 1243 (76.2) <.001
Diabetes 1392 (37.4) 567 (41.0) 286 (40.7) 539 (33.0) <.001
Dyslipidemia 1452 (39.1) 582 (42.1) 293 (41.7) 577 (35.4) <.001
Atrial fibrillation or flutter 1550 (41.7) 438 (31.7) 292 (41.5) 820 (50.3) <.001
COPD 304 (8.2) 107 (7.7) 47 (6.7) 150 (9.2) .1
Malignant tumor 535 (14.4) 180 (13.0) 104 (14.8) 251 (15.4) .17
Anemiab 2546 (68.5) 843 (61.0) 485 (69.0) 1218 (74.7) <.001
CKDc 1637 (44.0) 588 (42.5) 333 (47.4) 716 (43.9) .11
Laboratory data,
median (IQR)
BNP level, pg/mL 269 (136-522) 369 (194-664) 294 (152-578) 199 (96-384) <.001
BUN level, mg/dL 25.2 (18.6-36.0) 24.9 (18.4-34.2) 26.0 (18.8-38.4) 26.0 (18.7-36.4) .15
Creatinine level, mg/dL 1.12 (0.86-1.59) 1.14 (0.87-1.59) 1.17 (0.86-1.72) 1.10 (0.83-1.54) <.001
eGFR, mL/min/1.73 m2 43.3 (29.3-59.0) 45.3 (30.5-61.0) 42.8 (25.9-58.6) 41.3 (29.2-57.0) .002
Hemoglobin level, g/dL 11.3 (9.9-12.8) 11.8 (10.4-13.6) 11.2 (9.7-12.8) 10.9 (9.6-12.3) <.001
Sodium level, mEq/L 139 (136-141) 139 (136-141) 139 (136-141) 139 (137-141) .005
Albumin level, g/dL 3.4 (3.0-3.7) 3.4 (3.1-3.7) 3.4 (3.0-3.7) 3.4 (3.0-3.7) .003
Medications
β-Blocker 2469 (66.4) 1080 (78.1) 504 (71.7) 885 (54.3) <.001
ACEI or ARB 2138 (57.5) 892 (64.5) 400 (56.9) 846 (51.9) <.001
MRA 1678 (45.1) 722 (52.2) 310 (44.1) 646 (39.6) <.001
Abbreviations: ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; BMI,
bodymass index (calculated as weight in kilograms
divided by height in meters squared); BNP, brain-type
natriuretic peptide; BUN, blood urea nitrogen; CKD,
chronic kidney disease; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular
filtration ratio; HFmrEF, heart failure with midrange
ejection fraction; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced
ejection fraction; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist.
SI conversion factors: to convert albumin to grams per
liter, multiply by 10; BNP to nanograms per liter,
multiply by 1; BUN to millimoles per liter, multiply by
0.357; hemoglobin to grams per liter, multiply by 10;
and sodium tomillimoles per liter, multiply by 1.
a Data are presented as number (percentage) of
patients unless otherwise indicated.
b Defined by theWorld Health Organization criteria
(hemoglobin <12 g/dL for women and <13 g/dL
for men).
c Defined as an eGFR less than 60mL/min/1.73 m2.
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CI, 11.4%-16.5%]; and HFpEF group: 223 patients [13.7%; 95% CI, 12.1%-15.4%]; P = .71), and SCD
(HFrEF group: 44 patients [3.2%; 95% CI, 2.4%-4.2%]; HFmrEF group: 14 patients [2.0%; 95% CI,
1.2%-3.3%]; and HFpEF group: 40 patients [2.5%; 95% CI, 1.8%-3.3%]; P = .23). Figure 2 shows the
Kaplan-Meier survival curves for all-cause death, cardiovascular death, and noncardiovascular death
among the 3 groups.












All-cause death 848 (22.8) 298 (21.5) 158 (22.5) 392 (24.0) .26
Cardiovascular 523 (14.1) 203 (14.7) 97 (13.8) 223 (13.7) .71
Heart failure 324 (8.7) 128 (9.3) 65 (9.2) 131 (8.0) .42
Sudden cardiac 98 (2.6) 44 (3.2) 14 (2.0) 40 (2.5) .23
Vascular death 13 (0.3) 4 (0.3) 2 (0.3) 7 (0.4) .77
Acute coronary
syndrome
9 (0.2) 5 (0.4) 0 (0.0) 4 (0.2) .28
Stroke or intracranial
hemorrhage
38 (1.0) 8 (0.6) 9 (1.3) 21 (1.3) .12
Other cardiovascular
cause
41 (1.1) 14 (1.0) 7 (1.0) 20 (1.2) .82
Noncardiovascular
cause
322 (8.7) 94 (6.8) 61 (8.7) 167 (10.2) .004
Malignant tumor 71 (1.9) 24 (1.7) 9 (1.3) 38 (2.3) .20
Infection 122 (3.3) 33 (2.4) 28 (4.0) 61 (3.7) .06
Fatal bleeding 7 (0.2) 1 (0.1) 2 (0.3) 4 (0.2) .45
Other gastrointestinal
cause
10 (0.3) 3 (0.2) 1 (0.1) 6 (0.4) .56
Renal failure 18 (0.5) 5 (0.4) 2 (0.3) 11 (0.7) .33
Liver failure 6 (0.2) 1 (0.1) 1 (0.1) 4 (0.2) .49




58 (1.6) 18 (1.3) 14 (2.0) 26 (1.6) .48
Unknown 3 (0.1) 1 (0.1) 0 (0.0) 2 (0.1) .63
Abbreviations: HFmrEF, heart failure with midrange
ejection fraction; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced
ejection fraction.




















HFmrEF group HFpEF groupHFrEF group
ACS indicates acute coronary syndrome; CVD, cardiovascular death; HFmrEF, heart failure with midrange ejection fraction; and HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; ICH, intracranial hemorrhage; SCD, sudden cardiac death.
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Figure 2. Kaplan-Meier Survival Curves for All-Cause Death, Cardiovascular Death, and Sudden Cardiac Death
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HFmrEF indicates heart failure with midrange ejection
fraction; HFpEF, heart failure with preserved ejection
fraction; and HFrEF, heart failure with reduced ejection
fraction.
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Factors AssociatedWith EachMode of Death
In themultivariable Cox proportional hazards regression analyses, the factors confirmed as the
independent variables associatedwith all-cause death in all the study patients were older age, female
sex, no prescription of ACEIs or ARBs, anemia, low albumin levels, high BUN levels, and low estimated
glomerular filtration rate (eGFR) (eTable 1 in the Supplement). Among these variables, older age, no
prescription of ACEIs or ARBs, low albumin levels, and high BUN levels were consistently associated
with all-cause death in all subgroups. Some of these same factors, including older age, no
prescription of ACEIs or ARBs, and high BUN levels, were consistently associated with cardiovascular
death in the entire population and the subgroups (eTables 2-4 in the Supplement). In addition,
factors such as no prescription of β-blockers or MRAs, anemia, and low eGFRwere independently
associated with cardiovascular death in the HFrEF group. Some of these same factors, including low
eGFR and no prescription of MRAs, were independently associated with cardiovascular death in the
HFpEF group. Older age, female sex, anemia, low albumin levels, high BUN levels, and no prescription
of ACEIs or ARBs were also associated with noncardiovascular death.
The results of bayesian modeling for estimating cardiovascular death and SCD are shown in
Figure 3. Guideline-directed heart failure medications, such as β-blockers, ACEIs or ARBs, andMRAs,
were associated with a lower incidence of SCD in patients with HFrEF and in patients with HFpEF.
Other factors associated with an increased risk of SCDwere hyponatremia, HFrEF in female patients,
hypoalbuminemia and wide QRS in patients with HFmrEF, increased heart rate, and hyponatremia
and female sex in patients with HFpEF. Similarly, β-blockers, ACEIs or ARBs, and MRAs were also
associatedwith a lower incidence of cardiovascular death in theHFrEF group and in theHFpEF group.
Discussion
The current analysis investigated the postdischargemode of death in 3717 hospitalized patients with
ADHF and among LVEF subgroups (HFrEF, HFmrEF, and HFpEF). Themajor findings of this study
were as follows: (1) overall mortality in hospitalized patients with ADHF after discharge was 22.8%
during a median follow-up of 470 days with a 96% follow-up rate; (2) cardiovascular deaths
accounted for 61.7% of total mortality and noncardiovascular deaths accounted for 38.0% of total
mortality; (3) heart failure exacerbation was the leading cause of cardiovascular death, and SCDwas
the secondmost frequent cause of cardiovascular death; and (4) this finding was consistent among
the LVEF subgroups (HFrEF vs HFmrEF vs HFpEF), with the risk of SCD being comparable in the
HFpEF and HFrEF groups.
ADHF is a complex clinical syndrome, andmultiple factors and underlying mechanismsmay
contribute to postdischarge mortality in individual patients.10-12 Despite improvement in intensive
treatment of acute phases and multidisciplinary approaches to improve postdischarge outcomes,
patients hospitalized for ADHF have a substantial mortality risk of 10% to 20% during the 6months
after discharge.2-5 Thus, a better understanding of themode of death and a better characterization
of risks associated with mode-specific causes of death may provide insights into the underlying
mechanism to improve patient outcomes. In particular, comparisons of themode of death among
strictly defined populations with HFrEF, HFmrEF, and HFpEF are important for clinical practice.
In the Efficacy of VasopressinAntagonism inHeart FailureOutcomeStudyWith Tolvaptan (EVER-
EST) trial, which included4133patientswithHFrEFhospitalized for ADHF, 1080deaths occurredduring
amedian follow-upof 9.9months. Heart failure exacerbationwas the leading cause of death (47.2%),
and SCDwas the second-leading cause of death (30.0%).13 In the Efficacy, Safety andTolerability of
SerelaxinWhenAdded to Standard Therapy inAcuteHeart Failure (RELAX-AHF) trial, which included
1161 patientswith acute heart failure, heart failure exacerbationwas a leading cause of cardiovascular
death (35%), and SCDwas the second-leading cause of cardiovascular death (23%).14 Similarly, the cur-
rent analysis demonstrated that heart failure exacerbationwas the leading cause of cardiovascular
death, and SCDwas the second-leading cause of death.Of interest, SCDwas reported to be the second-
leading cause of death even in theHFpEFgroup, and the ratewas comparable to that in theHFrEF
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group.However, the nonnegligible prevalence of SCD is debatable. A similar incidence of SCDwas re-
ported in patientswith andwithout left ventricular systolic dysfunction,with a similar potential benefit
from implantable cardioverter defibrillator (ICD) prophylaxis.15
HFpEF has been reported to be associated with similar or slightly lower mortality than
HFrEF.16,17 Although heart failure death and SCD account for most cardiovascular deaths among
patients with HFpEF, similar to patients with HFrEF,18 themajor difference in the cause of death
between patients with HFrEF and those with HFpEF has been the larger prevalence of
noncardiovascular deaths in the HFpEF group.16,17,19,20 In the FraminghamHeart Study, 1025 deaths
in the mixed HFrEF and HFpEF population between 1971 and 2004 were analyzed, and 38% of
deaths reportedly had a noncardiovascular mode.21 Similarly, another study reported that 40% of
deaths were attributable to noncardiovascular modes during 20months after discharge in 459
patients admitted with ADHF, mixed HFrEF, and HFpEF.22 A previous study23 reported that 42% of
Figure 3. BayesianModeling for Cardiovascular Death and Sudden Cardiac Death Among Patients















































































Solid lines indicate that the association between
factors andmortality in each study group are
statistically significant, and dashed lines indicate that
those associations are not statistically significant.
Factors are shown in black if they have at least one
significant association with mortality, and factors are
shown in gray if they do not have any significant
associations with mortality in each study group.
Numbers in parentheses indicate path coefficients of
each factor to the mortality in each study group. ACEI
indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; BUN, blood urea
nitrogen; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; HFmrEF, heart failure
with midrange ejection fraction; HFpEF, heart failure
with preserved ejection fraction; HFrEF, heart failure
with reduced ejection fraction; IHD, ischemic heart
disease; MRA, mineralocorticoid receptor antagonist.
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deaths in patients with HFpEF had noncardiovascular causes. Consistent with previous reports,16,19
the rate of noncardiovascular death was higher in the HFpEF group in the current analysis. In a
previous study,23 infection was the leading cause of noncardiovascular death, causing 38% of total
noncardiovascular deaths, andmalignant tumor was the second-leading cause of noncardiovascular
death (22%), findings that were consistent with the those in the LVEF subgroups in the current study.
Reduced LVEF remains themajor selection criterion for ICD placement according to the current
guidelines,24 and increasing evidence supports that ICD is an effective treatment of primary and
secondary SCD in patients with left ventricular systolic dysfunction.25,26 However, given the
substantial amount of SCD observed in patients with LVEFs higher than 35%who do not qualify for
ICD placement based on the current criteria,26-29 our results pose the question of whether the ICD
criteria should be determined only by LVEF. Although no data are currently available to examine the
role of ICD treatment in patients with HFpEF, observational data suggest that SCD contributes
substantially to the overall mortality in these patients.30,31 However, considering the high incidence
of nonarrhythmic heart failure deaths and that ICD placement in patients with HFrEF yielded
conflicting results for overall mortality despite increased frequency of adequate ICD shocks,
additional studies are needed to identify patients whowould optimally benefit from ICD implantation
irrespective of the LVEF level.
Strengths and Limitations
This study has strengths. It provides insight regarding the prevalence, nature, and variables
associated with death in patients with postdischarge ADHF, with a high follow-up rate, strictly
adjudicatedmode of death, and potentially important implications for improvement in survival. The
study included central adjudication of end points and a large contemporary patient population across
the spectrum of LVEF.
This study has limitations. First, thiswas a post hoc analysis fromaprospective, observational co-
hort studywith inherent associated limitations. Despite covariate adjustment,we could not exclude the
influence of othermeasured andunmeasured confounding. In particular,wedid not consider any in-
terim cardiovascular events associatedwith heart failure death or SCD thatmayhavemodified the dis-
ease trajectories. Second, it is possible that our data are not generalizable to all patientswithADHF.
Particularly, the current cohort included a large number of patientswith denovoheart failure rather
than acuteworsening of chronic heart failure, leading to a small number of patientswith ICD implanta-
tion at the timeof discharge. In addition, the patient populationwas elderly, and theprevalence of an
ischemic origin of heart failurewas lower than that reported in other clinical series outside Japan. The
diagnosis of nonischemic cardiomyopathywasmadebyphysicians in eachparticipating center, andnot
all patientswith a nonischemic origin underwent coronary angiographyduring the hospitalization.We
did not havedata on the number of patientswhohad ICD implantation during the follow-up after dis-
charge. Third, diagnosis of heart failure originwas not basedonbiopsy results or imaging findings. In
addition,wedid not have information regardingwhether any of the patientswithHFpEForHFmrEF
recovered fromHFrEF. In addition, information regarding circumstances of SCDwas not available. Thus,
there is a possibility that specific patientswith cardiomyopathy, such as hypertrophic cardiomyopathy,
restrictive cardiomyopathy, and cardiac amyloidosis,were included in the registry. In particular, under-
diagnosed cardiac amyloidosismaybe associatedwith a high incidence of SCD in theHFpEF cohort.
Additional studies are needed to test this hypothesis.
Conclusions
In this study, the incidences of cardiovascular death and sudden cardiac death were comparable
among the heart failure subtypes. Use of β-blockers and ACEIs or ARBs was associated with lower
mortality in patients with HFpEF and HFmrEF. Given the nonnegligible incidence of SCD in patients
with HFpEF, an additional study appears to be warranted to identify the high-risk subset in this
population.
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